Amylyx Pharmaceuticals, Inc. (AMLX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 12:32PM EDT. Market open.
| Previous Close | 1.9900 |
| Open | 1.9900 |
| Bid | 1.9500 x 300 |
| Ask | 1.9600 x 100 |
| Day's Range | 1.9500 - 2.0150 |
| 52 Week Range | 1.7000 - 30.5000 |
| Volume | |
| Avg. Volume | 3,505,947 |
| Market Cap | 132.951M |
| Beta (5Y Monthly) | -0.93 |
| PE Ratio (TTM) | 2.79 |
| EPS (TTM) | 0.7000 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Business WireAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksBiotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
© 2024 Yahoo. All rights reserved.